Novo drops 4.7 percent as U.S. panel focuses on degludec safety

COPENHAGEN (Reuters) - Shares in Denmark's Novo Nordisk dropped 4.7 percent on Friday after a U.S. expert panel assessing the group's ultra long-acting insulin degludec said it will study the cardiovascular safety of the drug.

via Reuters: Health News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/10/novo-drops-47-percent-as-us-panel.html